MDM shares its findings in journals and at professional conferences.



Abstracts and Presentations

MDM personnel regularly present their research at scientific conferences such as the Society for Medical Decision Making (SMDM) and the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Additionally, MDM personnel are regular reviewers for conference presentations at SMDM and ISPOR.

Bold type denotes MDM employee at time of research contribution.

  • Vivas-Valencia C, Kong N, Imperiale T, Klein R, Tham W. Development of a progressive calibration procedure for model-based cost-effectiveness studies on individualized colorectal cancer screening program. (Oral Presentation WB39-1 at INFORMS Annual Meeting, San Francisco, CA, Nov. 12 2014)

  • Smolen HJ. Development of an influenza outbreak forecasting model using time series analysis methods. (Poster PRM 102 at ISPOR 17th Annual European Congress, Amsterdam, The Netherlands, Nov, 11, 2014)

  • Kong N, Imperiale T, Klein R, Vivas-Valencia C. A simulation-based cost-effectiveness study on age and gender-specific CRC screening strategies. (Oral Presentation SD41-1 at INFORMS Annual Meeting, San Francisco, CA, Nov. 9 2014)

  • Vivas-Valencia C, Kong N, Klein R, Tham W, Imperiale T. A progressive calibration procedure for individualized colorectal cancer screening study. (Oral Presentation TRA-2-4 at the 36th Annual Meeting of the Society for Medical Decision Making, Miami, FL, Oct. 20 2014)

  • Klein R, Ng D, Perk S, Wielage R, Klein T, Yuran T, Berner T. Economic and clinical impact of switching from antimuscarinics to Mirabegron for the treatment of overactive bladder. (Poster Presentation at the 36th Annual Meeting of the Society for Medical Decision Making, Miami, FL, Oct. 22 2014)

  • Smolen L, Wielage R, Gahn J, Gaith M, Shiozawa A. The budgetary impact of Febuxostat in the management of patients with gout. (Poster Presentation 2014 AMCP Educational Conference, Tampa, FL, April 1-4 2014)

  • Smolen L, Wielage R, Gahn J, Gaith M, Shiozawa A. The cost effectiveness of Febuxostat in the management of patients with gout. (Poster Presentation 2014 AMCP Educational Conference, Tampa, FL, April 1-4 2014)

  • Myers J, Duhig A, Pitts A, Klein RW, Harvey P. Performance on the UCSD performance-based skills assessment (UPSA) and real-world outcomes in severe mental illness: a systematic review of the literature. (Poster Presentation 4th Biennial Schizophrenia International Research Society Conference, Florence, Italy, April 5-9 2014)

  • Flynn JA, Burge R, Nojiri S, Klein TM, Smolen LJ. Simulation study of the clinical impact of Forteo (teriparatide [rDNA origin] injection) use for two years by postmenopausal osteoporosis (PMO) patients in Japan. 2013 Sep. (Poster Presentation AFOS 2013 Conference, Seoul, Korea, September 6-8, 2013)

  • Furiak N, Klein RW, Gahn JC, Camper SB, Summers K. Use of a decision tree model to estimate the economic benefits of reducing schizophrenia illness relapse. Value Health 2013 May;16(3):A62-3. (Poster PMH43 ISPOR 18th Annual International Meeting, New Orleans LA, May 20 2013)

  • Ariely R, Klein R, Gahn JC, Tham WK, Cohen D, Bell C, Tynan A. A model framework evaluating factors affecting the value of treatment one year following an acute coronary syndrome event. Value Health 2013 May;16(3):A288. (Poster PCV91 ISPOR 18th Annual International Meeting, New Orleans LA, May 22 2013)

  • Smolen H. Reanalyzing carotid artery stenosis treatment clinical trial results from a bayesian perspective. (Podium Presentation MO2 ISPOR 18th Annual International Meeting, New Orleans LA, May 2013)

  • Ariely R, Klein R, Tham W, Bell C, Smolen L, Tynan A. Identifying and adapting a prognostic risk equation for relevant subppulations in a pharmacoeconomic model of major adverse cardiovascular event prevention. (Poster #176, American Heart Association-Quality of Care and Outcomes Research 2013, Baltimore, MD, May 16 2013)

  • Furiak N, Duhag A, Myers JA, Hass S, Klein RW, Pitts AC. The economic burden of disease associated with cognitive deficits in patients in schizophrenia. (ID 1517855 14th International Congress on Schizophrenia Research, Orlando, Florida, April 25, 2013)

  • Wielage R, Samsa G, Klein T, Happich M. A maximum likelihood simulation technique for estimating adverse event rates from published trials. Value in Health 2012;15(7): A487 (Poster PRM145, ISPOR 15th Annual European Congress, Berlin, Germany, Nov 6, 2012)

  • Myers JA, Klein RW, Han X, Al Haddad M, Smolen, HJ. Evaluating strategies for using DNA testing to identify mucinous pancreatic cysts. Value in Health 2012;15(7): A352-A353. (Poster PMD44 ISPOR 15th Annual European Congress, Berlin, Germany, Nov 5, 2012)

  • Myers JA, Wielage RC, Han B, Price K, Gahn J, Paget M, Happich M. The efficacy of duloxetine, non-steroidal anti-inflammatory drugs, and opioids in osteoarthritis: A meta-analysis. Value in Health 2012;15(4): A33. (Poster PMS2, ISPOR 17th Annual International Meeting, Washington, DC, June 5, 2012)

  • Smolen LJ, Klein TM, Voelker JR, Sierra-johnson J, Boye ME. Economic Benefits of Slowing Progress to End Stage Renal Disease (ESRD) in Patients with Diabetes-Related Chronic Kidney Disease (DKD), Compared with Standard of Care (SOC). Value in Health 2012;15(4): A155.

  • Furiak NM, Bansal M, Gahn JC, Klein RW, Smolen HJ. Validation of a Diabetes Modeling Framework. Value in Health 2012;15(4): A173. (Poster PDB18 ISPOR 17th Annual International Meeting, Washington, DC, June 5, 2012)

  • Furiak N, Bansal M. Quantifying cost outcomes differentiated by gender and age in the treatment of migraine headache using step and stratified care. Value in Health 2011;14:A206. (Poster PND22 ISPOR 16th Annual International Meeting, Baltimore, Maryland, May 25, 2011)

  • Furiak N, Bansal M, Gahn JC, Smolen H. Beta-verification of a diabetes modeling framework against published cohort. Value in Health 2011;14:A104. (Poster PDB74 ISPOR 16th Annual International Meeting, Baltimore, Maryland, May 24, 2011)

  • Smolen HJ, Myers JA, Smolen LJ. Cost-effectiveness modeling in osteoporosis: a systematic literature review and overview. Value in Health 2011;14:A127-A128. (Poster PMS26 ISPOR 16th Annual International Meeting, Baltimore, Maryland, May 24, 2011)

  • Furiak N. Therapy persistence with disease-modifying AD therapy-Impact on NNT and AD-free years in an asymptomatic population. (Podium presentation at the opening plenary session of the Neurodegenerative Diseases: Biology & Therapeutics Meeting, December 4, 2010, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.)

  • Smolen H. An introduction to discrete event simulation and other healthcare modeling techniques. (Workshop presentation at the 8th Conference of the Polish Pharmacoeconomics Society, ISPOR Poland 2010, December 2, 2010, Sobieski Hotel, Warsaw, Poland.)

  • Lee LJ, Klein RW, Klein TM, Furiak N, Peltz G, Bansal M, Jackson JA, Juneja R. Evaluation of cost and clinical outcomes by HbA1c at diagnosis using various diabetes treatment strategies. Value Health. 2010;13(7):A289. (Poster PDB33 ISPOR 13th Annual European Congress, Prague, Czech Republic, Nov 17, 2010).

  • Smolen LJ, Gregor Z, Barrett A, Myren KJ, Toll A. Cost-effectiveness of teriparatide in patients with glucocorticoid-induced osteoporosis in Sweden. Value Health. 2010;13(7):A308. (Poster PMS35 ISPOR 13th Annual European Congress, Prague, Czech Republic, Nov 17, 2010).

  • Olsson AG, Jensen MM, Gandhi SK, Smolen L, Paulsson T. The cost-effectiveness of rosuvastatin versus simvastatin for the prevention of cardiovascular morbidity and mortality in patients with high baseline risk-a Swedish economic evaluation based upon the JUPITER trial. Value Health. 2010;13(7):A358. (Poster PCV90 ISPOR 13th Annual European Congress, Prague, Czech Republic, Nov 17, 2010).

  • Smolen LJ, Foster SA, Whiteman D, Lee JL. Comparison of 3mL versus 10mL insulin vial size on hospital pharmacy budget. (Poster SMOL1037H International Hospital Diabetes Meeting, San Diego CA October 8, 2010).

  • Smolen LJ, Klein RW. Synchronization of random number streams greatly enhances efficiency of probabilistic models. Value Health. 2010;13(3):A16. (Poster PMC15 ISPOR 15th Annual International Meeting, Atlanta, GA, May 17, 2010).

  • Klein RW, Lawson AH, Muehlenbein CE, Liepa AM, Wielage RC, Babineaux S, Koustenis A. The budgetary impact of pemetrexed maintenance therapy for advanced nonsquamous non-small cell lung cancer. Value Health. 2010;13(3):A28. (Poster PCN25 ISPOR 15th Annual Meeting, Atlanta GA, May 2010).

  • Furiak NM, Bansal M. The estimated cost-savings of stratified care for migraine headaches from a U.S. perspective. Value Health. 2010;13(3):A138. (Poster PND6 ISPOR 15th Annual Meeting, Atlanta, GA May 2010).

  • Ohsfeldt R, Gandhi SK, Jensen MM, Smolen L, Fox KM, Hsia J, Gold A. Cost-effectiveness of rosuvastatin 20 mg in secondary-prevention patients in the United States. Value Health. 2010;13(3):A162. (Poster PCV70 ISPOR 15th Annual International Meeting , Atlanta, GA, May 19, 2010).

  • Ohsfeldt R, Gandhi SK, Jensen MM, Smolen L, Fox KM, Gold A, Hsia J. Cost-effectiveness of rosuvastatin 10 mg in the reduction of cardiovascular morbidity in patients at risk of cardiovascular disease. Value Health. 2010;13(3):A165. (Poster PCV84 ISPOR 15th Annual International Meeting , Atlanta, GA, May 19, 2010).

  • Smolen H, Klein R, Myers J. Accounting for trial-excluded medical conditions when simulating mortality in clinical trial populations. Value Health. 2010;13(3):A179 (Poster PCV157 ISPOR 15th Annual International Meeting, Atlanta, GA, May 19, 2010).

  • Klein RW, Lawson AH, Muehlenbein CE, Liepa AM, Wielage RC, Babineaux S, Koustenis A. Budgetary impact of pemetrexed as maintenance therapy for advanced non-small cell lung cancer. (Poster PRR22 Academy of Managed Care Pharmacy April 9, 2010).

  • Smolen HJ, Klein TM, Klein RW, Cohen DJ. Determining a model-derived relative stroke riskthreshold to justify carotid stenting in surgical high-risk patients. Value Health. 2009;12(7):A320. (Poster PCV45 ISPOR 12th Annual European Congress, Paris France Oct 24, 2009).

  • Klein R, Muehlenbein C, Wielage R, Liepa A, Babineaux S, Schwartzberg L. The importance of histology in evaluating the cost-effectiveness of pemetrexed maintenance after first-line therapy for advanced non-small cell lung cancer. (Poster 31st Annual Meeting of the Society for Medical Decision Making, Hollywood, CA, Oct 20, 2009).

  • Kahle-Wrobleski K, Klein R, Furiak N, Siemers E, Klein T. Biomarker screening for Alzheimer's Disease: when to screen and how often? (ICAD July 2009)(IHIF Neuroscience December 2009)(NCDEU May 2010).

  • Ascher-Svanum H, Furiak NM, Klein RW, Montgomery W, Smolen LJ, Lawson AH, Conley RR. Cost-effectiveness of olanzipine long-acting injection in the treatment of non-adherence patients with schizophrenia in the United States. Value Health. 2009;12(3):A176. (Poster PMH21 ISPOR 14th Annual International Meeting, Orlando FL, May, 2009).

  • Muehlenbein C, Wielage R, Liepa A, Babineaux S, Klein R, Schwartzberg L. The budgetary impact of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small cell lung cancer. Value Health. 2009;12(3):A39. (Poster PCN20 ISPOR 14th Annual International Meeting, Orlando FL, May, 2009).

  • Klein TM, Wielage RC, Furiak NM, Klein RW. Using an encounter-based database to validate a disease progression model: Lessons for modelers. Value Health. 2009;12(3):A25. (Poster PMC30 ISPOR 14th Annual International Meeting, Orlando FL, May, 2009).

  • Kahle-Wrobleski K, Siemers ER, Sarpong E, Furiak N, Klein T, Klein R, Callahan C. Biomarker screening for Alzheimer's Disease: Sensitivity and specificity parameters (AAN).

  • Smolen HJ, Einterz RM. A simulation-based approach to modeling the effects of intervention strategies on the spread of meningococcal meningitis. Value Health. 2008;11(6):A428. (Poster PIN3 ISPOR 11th Annual European Congress, Athens Greece Nov 2008).

  • Furiak NM, Kahle-Wrobleski K, Siemers ER, Klein TM, Sarpong E, Klein RW. Modeling screening and prevention of Alzheimer's Disease. (Poster 30th Annual Meeting of the Society for Medical Decision Making, Philadelphia PA, Oct 20, 2008).

  • Ascher-Svanum H, Furiak NM, Klein RW, Smolen LJ, Watson, P. Cost-effectiveness of orally dissolving olanzipine tablets in the treatment of schizophrenia in the USA. Value Health. 2008;11(3):A121. (Poster PMH35 ISPOR 13th Annual International Meeting, Toronto CA, May, 2008).

  • Kessler WR, Klein RW, Wielage RC, Rex DK. Cost savings of removing diminutive polyps without laboratory histology. American Public Health Association. 136th Annual Meeting; San Diego CA; 2008.

  • Kessler WR, Klein RW, Wielage RC, Rex DK. Cost savings of removing diminutive polyps without histological assessment. Gastrointest Endosc. 2008;67(5):AB105.

  • Ascher-Svanum H, Furiak NM, Klein RW, Smolen LJ, Zhu B. Cost-effectiveness of olanzapine versus generic risperidone and other antipsychotics in standard oral formulations in patients with schizphrenia in the US. Value Health. 2007;10(6):A294. (Poster PMH23 ISPOR 10th Annual European Congress, Dublin Ireland, Oct 21, 2007).

  • Klein RW, Yaesoubi R, Roberts SD. Factor screening for parsimony of variables in pharmacoeconomic models. Value Health. 2007;10(3):A55. (Poster PCV62 ISPOR 12th Annual International Meeting, Arlington VA, May 21, 2007).

  • Yaesoubi R, Roberts SD, Klein RW, Chalasani NP, Imperiale TF. Factor screening to identify factors which influence strategy selection. (Poster III-2 28th Annual Meeting of the Society for Medical Decision Making, Cambridge MA, October 17, 2006).

  • Klein RW, Imperiale TF, Chalasani N. A cost effectiveness analysis of screening for esophageal varices: how good does a clinical decision aid have to be? Value Health. 2006;9(3):A45. (Poster PG18 ISPOR 11th Annual International Meeting, Philadelphia PA, May 22, 2006).

  • Thomas NA, Zhu B, Ascher-Svanum H, Faries D, Montgomery W, Furiak NM. Adherence levels and differential use of mental health services in the treatment of schizophrenia. Value Health. 2006;9(3):A76. (Poster PMH38 ISPOR 11th Annual International Meeting, Philadelphia PA, May, 2006).

  • Imperiale TF, Klein RW, Chalasani N. A cost-effectiveness and cost-utility analysis of variceal ligation versus beta-blockers for primary prophylaxis of variceal bleeding. Gastroenterology. 2006;130 (4):A810.

  • Russell JM, Furiak N, Klein R, Yurgin N, Marciniak M, Bowman L. Using a generalized anxiety disorder disease state model to quantify the effects of effective diagnosis and treatment on overall remission rates. Eur Neuropsychopharmacol. 2005,15(S3):S553.

  • Klein RW, Ohsfeldt RL, Smolen LJ, McCollam PL. Potential 30-day cost savings from acute coronary syndrome treatment improvements. American College Clinical Pharmacists, San Francisco, May 2005.

  • Rousculp MD, Klein RW, Smolen LJ, Ohsfeldt RL, Johnston JA. Cost-effectiveness of pharmacological treatment in postmenopausal women. Med Decis Making. 2005. (Poster I-11 SMDM 28th Annual Meeting, San Francisco CA, October, 2005).

  • Klein RW, Ohsfeldt RL, Smolen LJ, McCollam PL. Potential cost savings from acute coronary syndrome treatment improvements. Value Health. 2005;8(3):262. (Poster PCV5 ISPOR 10th Annual International Meeting, Washington DC, May, 2005).

  • Smolen HJ, Ohsfeldt RL, Klein RW, Poret AW, Weinberger MH. An ARB cost-effectiveness model treating mild-to-moderate hypertension. Value Health. 2004;7(3): 26. (Poster PCV28 ISPOR 9th Annual International Meeting, Arlington VA, May, 2004).

  • Ness RM, Klein RW, Wang L, Dittus RS. The cost-effectiveness of fecal DNA testing for colorectal cancer. Gastroenterol. 2003; 124:A234.

  • Ohsfeldt RL, Kreder KJ, Klein R, Chrischilles EC. Cost-effectiveness of tamsulosin, doxazosin, and terazosin in the treatment of benign prostatic hyperplasia. Value Health. 2003;6(3):288. (Poster PRK9 ISPOR 8th Annual International Meeting, Arlington VA, May, 2003).

  • Imperiale TF, Chalasani N, Klein RW. Cost-effectiveness analysis of measuring hemodynamic response to primary pharmacoprophylaxis for variceal bleeding. Med Decis Making. 2001;21(6):528.

  • Ness RM, Klein RW, Holmes AM, Dittus RS. Is an increased frequency of post-polypectomy surveillance cost-effective in patients with a family history of colorectal cancer? Gastroenterology. 2000; 118:A265.

  • Ness RM, Klein RW, Holmes AM, Dittus RS. Is an increased frequency of rescreening cost-effective in patients with a family history of colorectal cancer? Gastroenterology. 2000;118:A264.

  • Ness RM, Klein RW, Holmes AM, Dittus RS. What is the cost-utility of post-polypectomy colonoscopy surveillance strategies in persons with a family history of colorectal cancer? Med Decis Making. 1999,19(4):527.

  • Ness RM, Klein RW, Holmes AM, Dittus RS. What is the cost-utility of colonscopic re-screening in persons with a family history of colorectal cancer but no adenoma on initial screening? Med Decis Making. 1999,19(4):544.

  • Ness RM, Klein RW, Holmes AM, Dittus RS. Is rescreening cost-effective when no polyps are found at initial screening? Gastroenterology. 1999;116:A84.

  • Ness RM, Klein RW, Holmes AM, Dittus RS. Is post-polypectomy surveillance cost-effective? Gastroenterology. 1999;116:A84.

  • Ness RM, Klein RW, Holmes AM, Dittus RS. What is the effect of initial screening age on the cost-effectiveness of post-polypectomy surveillance. Gastroenterology. 1999;116:A84.